PeptiDream Inc.
Announcement of Phase 1 Clinical Trial Initiation by Drug Discovery Joint Research Partner
PeptiDream has initiated a Phase 1 clinical trial for the type 1 TNF receptor inhibitor 'AK1940', co-developed with Asahi Kasei Therapeutics. The company holds the right to receive milestone fees, with no changes to earnings guidance.
Key Figures
- Phase 1 Clinical Trial Start Date: 2026-04-20
- Milestone Fees: Amount undisclosed
- Earnings Guidance: No change for the fiscal year ending December 2026
AI要約
Overview of Phase 1 Clinical Trial Initiation
PeptiDream Inc. announced the initiation of a Phase 1 clinical trial for 'AK1940', a type 1 TNF receptor inhibitor co-developed with Asahi Kasei Therapeutics. This compound is a cyclic peptide created using PeptiDream's proprietary drug discovery platform PDPS and is expected to contribute broadly as a treatment for autoimmune diseases.
Outlook and Impact on Earnings
With the start of the Phase 1 clinical trial, PeptiDream holds the right to receive milestone fees, although the amount is undisclosed. There is no change to the earnings guidance for the fiscal year ending December 2026, and milestone fees and royalties are expected to be received according to future clinical progress.
PeptiDream Inc.
Company overview · Stock price · Financial data · All IR
